Trial Profile
An Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of the Farnesyl-Transferase Inhibitor Zarnestra (R115777) in Subjects With High-Risk Myelodysplastic Syndrome (MDS)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Aug 2008
Price :
$35
*
At a glance
- Drugs Tipifarnib (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- Sponsors Janssen Research & Development
- 19 Aug 2008 New trial record.